volume 11, issue Suppl 1, PP39 2008
DOI: 10.1186/1758-2652-11-s1-p39
View full text
|
|
Share

Abstract: This study aimed at testing the immuno-virological response in 20 consecutive HIV-1 infected patients treated with darunavir (DRV) within the early access program through 12 months of therapy. Evolution of drug resistance on HIV-RNA, on proviral DNA and proviral DNA quantification at different time points were carried out. Methods20 virologically multifailed subjects received a new HAART regimen composed by two NRTI and DRV as boosted PI; 16/20 were under T20 treatment. Immunovirological response was determin…

Expand abstract

Search citation statements

Order By: Relevance

Paper Sections

0
0
0
0
0

Citation Types

0
0
0

Publication Types

Select...

Relationship

0
0

Authors

Journals